INTRODUCTION
Uncontrolled gout is a debilitating medical condition resulting from monosodium urate (MSU) crystal deposition throughout the body, manifesting as recurrent attacks of acute inflammatory arthritis of the peripheral joints.
Gout affects about 1-4% of the population in Western developed countries, and is more prevalent in men [1] [2] [3] . The hallmark precursor to gout is hyperuricemia, defined as serum urate (sUA) levels [6.8 mg/dl (&400 lmol/l); this predominantly results from inefficient renal uric acid excretion, rather than overproduction [4, 5] . Clinical diagnosis of gout is confirmed by the presence of characteristic MSU crystals in the joint fluid [2, 6] . While there is evidence of familial clustering in gout, risk factors include cardiovascular/metabolic diseases (e.g., obesity, arterial hypertension, diabetes, hypercholesterolemia, and renal failure) and menopause, as well as diets rich in purines, alcohol consumption, and thiazide diuretic use [4] .
Management of gout encompasses both
short-term control of acute attacks and long-term treatment to reduce sUA, thereby dissolving MSU crystals and preventing further acute manifestation of flares [4] . Treatment of acute attacks involves use of colchicine, nonsteroidal anti-inflammatory drugs (NSAID), or corticosteroids [7, 8] . At the first flare, dietary and lifestyle modifications are advised to prevent recurrence. For long-term management of gout,
European League Against Rheumatism (EULAR)
and American College of Rheumatology (ACR) treatment guidelines recommend urate-lowering therapies (ULTs) to decrease sUA to \6 mg/dl, while target levels \5 mg/dl are recommended for patients with recurrent acute attacks, tophi, or radiographic gout changes [7, 8] . British Society of Rheumatology guidelines recommend target sUA \5 mg/dl [9] . All guidelines recommend xanthine oxidase inhibitors (e.g., allopurinol, febuxostat), which inhibit uric acid production, as first-line therapy. When xanthine oxidase inhibitors are contraindicated or fail to achieve sUA targets, the addition or use of a uricosuric agent (e.g., probenecid, benzbromarone), which increases renal excretion of uric acid, is recommended [8] . Unfortunately, there is widespread evidence that patients with gout are not treated according to these guidelines and therefore their gout remains poorly controlled [10] [11] [12] [13] . Gout progression can cause permanent joint destruction, bone erosion, and organ damage if hyperuricemia is left uncontrolled [14] . In addition to causing pain, disability, and diminished quality of life, poorly controlled gout is associated with significantly higher healthcare costs and loss in productivity [15] [16] [17] . In a US prospective study, patients with frequent gout attacks had a higher prevalence of comorbidities (chronic kidney disease, hypertension, dyslipidemia, ischemic heart disease, heart failure, and arthritis) than those with infrequent attacks [18] . They also had higher mean numbers of all-cause and gout-attributed outpatient and emergency department visits, as well as substantially greater healthcare costs than those with infrequent attacks [18] . Another study found higher outpatient, emergency, and inpatient services utilization among patients with gout than matched non-gout patients [19] ; all-cause healthcare costs were also higher for gout patients, and increased with increasing sUA. Overall, however, data on the health and cost burden associated with gout are scarce. Moreover, significant proportions of patients continue to experience elevated sUA, recurrent flares, and tophi despite ULT [20, 21] .
By analyzing data extracted from electronic medical record (EMR) and administrative claims databases, our study sought to investigate large populations of gout patients in the USA, UK, Germany, and France. Our objectives were: to assess the rate of uncontrolled gout and identify predictors of disease control (including ULT characteristics) in these populations; to estimate health resource utilization (HRU) and healthcare costs in that patient group; and to identify predictors of HRU and healthcare costs.
METHODS

Data Sources
This study investigated gout patients in the USA, UK, Germany, and France using retrospective healthcare data extracted from EMR and administrative claims databases: US IMS PharMetrics Plus database [22] [23] [24] ; UK Clinical Practice Research Database (CPRD)
and Hospital Episode Statistics database [25, 26] ; and IMS Disease Analyzers in Germany [27, 28] and France [29, 30] , respectively. Details on these databases are in supplemental Table S1 .
Study Design
This was an observational cohort study of established gout patients in four countries. For the USA, UK, and Germany, the study period were assessed in the first post-index panel-year (full year 2010), while outcomes were assessed in the second post-index panel-year (full year 2011). For France, the same procedures were used, but the timeline was moved forward by 1 year to synchronize the study window with information collected through an observational study (only available for 2012), which was conducted in a subset of general practitioners/ primary care physicians (GPs/PCPs) and included additional information on hospitalizations and laboratory results.
Patient Selection
In all four countries, the study population consisted of adult patients (C18 years at index-date) identified with established gouti.e., receiving ULT or eligible for ULT according to ACR guidelines [8] -during the course of the preindex panel-year. ACR criteria were based on: a documented diagnosis code for gout or a prescription for colchicine or a colchicine combination; and a diagnostic code for moderate chronic kidney disease, urolithiasis, or tophus or the occurrence of two gout flares. For all analyses involving disease control status, the analysis population was limited to those with C1 sUA measurement during the period of assessment of control status.
Definition of Disease Control Status
Among those with C1 sUA measurement during the period of assessment of control status, a defined control status over the course of a panel-year was determined as follows: gout was considered controlled if no sUA elevation ([6 mg/dl), no diagnosis code for tophus, or no flare was documented, and as uncontrolled if C2 flares or a sUA elevation was reported.
Control status was assessed in the second post-index panel-year and its predictors were identified in the first post-index panel-year; control status was also assessed in the first post-index panel-year as a potential predictor in different multivariate models.
Remaining cases (e.g., one flare without sUA elevation) were labeled as ''undefined control status''. Gout flare occurrence was defined by an office visit or hospitalization with a diagnosis of gout, followed by prescription of NSAID, colchicine, oral corticosteroid, or interleukin-1 antagonist within 3 days; or by an office visit or hospitalization with a diagnosis of joint pain, followed by prescription of colchicine within 3 days [31, 32] . Discontinuation was defined as a gap of [50% of the days' supply of the last prescription (starting from the end date of the supply in the last prescription).
• Patients prescribed a ULT during the course of the panel-year but who did not qualify as chronic ULT-treated were categorized as patients ''with less than 60 consecutive days' supply of ULT'' and reported as a distinct category.
• Patients without a prescription for a ULT during the panel-year were categorized as ''untreated patients''.
Persistence with ULT within each panel was defined as the number of consecutive days on any ULT, from treatment initiation until the first observed defined gap in days' supply during the follow-up period (discontinuation) or the end of the panel, whichever occurred first. Adherence to ULT was calculated as persistence divided by the number of days in the panel (i.e., 365).
Identification of HRU
All healthcare resources utilized over the course of the second post-index panel-year were identified and split between gout-attributed Table 1 continued Ref.
Ref.
Ref. \0.001 Table 2 continued and non-gout-attributed HRU. All visits or hospitalizations associated with a diagnosis of gout or joint pain were attributed to gout.
Gout-attributed laboratory services included all sUA tests. Gout-attributed pharmacy services included all prescriptions for gout-related medications (i.e., ULT, anti-inflammatories, and colchicine). Non-gout-attributed utilization included all other outpatient, inpatient, and pharmacy services.
Country-specific limitations inherent to databases hindered collection of exactly the same information in all four countries; details are available in supplemental Table S1 .
Valorization of HRU
For the USA, healthcare costs/charges associated with utilization were determined by the allowed amount (the amount the health plan allows for a particular service, including the paid amount 
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RESULTS
Study Population
The total number of gout patients fulfilling the Multivariate logistic regression among the patients with defined control status in the second post-index panel-year showed that in the USA, UK, and Germany, the following characteristics in the first post-index year were associated with higher probability of being controlled in the second post-index year:
female gender, chronic ULT-treated, and [80% adherent to ULT in the previous panel-year, as well as having fewer comorbidities reflected by CCI score (Table 2 ). In the USA and Germany, the probability of being controlled increased with age. The model could not be evaluated for Ref.
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Controlled
HRU in the Second Post-index Panel-Year
The proportion of patients in the total eligible population with C1 non-gout-attributed/goutattributed GP/PCP visit, respectively, was 58.8/ 28.2% in the USA, 99.2/7.8% in UK, 97.9/0.5%
in Germany, and 96.4/7.0% in France ( Table 3) . The proportion of patients with gout-attributed GP/PCP visits was consistently higher in uncontrolled than controlled patients (USA: 43.0% vs. 37.3%, P = 0.011; UK: 17.9% vs.
4.6%, P\0.001; Germany: 0.7% vs. 0.2%, P\0.001; France: 10.4% vs. 5.0%, P = 0.003).
The proportion of patients with C1
non-gout-attributed hospitalization was 10.0% in the USA, 27.2% in UK (calculated on the patient subset with linked hospitalization data, i.e., 60.4% of total eligible population), 12.6%
in Germany, and 10.3% in France (calculated on the patient subset with additional hospitalization data; n = 943) ( Table 3 ). About 31.2% of US patients and 4.6% of UK patients consulted a specialist for a gout-attributed reason ( Table 3) Table 4 ).
Healthcare Costs in the Second Post-index Panel-Year
The average all-cause healthcare cost per patient, expressed as 2011 USD and calculated over of the whole panel-year, was $13,514 in the USA, $2620 in UK, $1671 in Germany, and $1463 in France. Gout-attributed costs were lower than non-gout-attributed costs in all four countries (Table 3) . Based on multivariate analysis, patient characteristics resulting in higher gout-attributed costs were CCI score in the previous panel-year (USA, UK, Germany), being uncontrolled in the previous panel-year (UK, Germany, France), and being chronic ULT-treated in the previous panel-year (USA, Germany) (Table 4) .
DISCUSSION
Despite the high rate of ULT in the study population, [50% of patients with evaluable control status (i.e., with available sUA assessments) in all four countries remained uncontrolled, suggesting inadequacy of gout management in the real-world setting. The study also revealed poor compliance to treatment guidelines. Average allopurinol doses were below 300 mg in each country (most notably in France, at 186.6 mg), despite guideline recommendations that the dose can be advanced to 300 mg daily and above for those without renal impairment, in order to achieve target sUA in a substantial proportion of patients. Suboptimal dosing of allopurinol is recognized to be a common issue in the management of gout worldwide [13, 34, 35] . In addition, whereas EULAR and ACR guidelines recommend treating to a target sUA, including continuing measurements once the sUA target is achieved (every 6 months), the high percentage of patients with no sUA data-even in countries where all laboratory values were included in the data (Germany, UK)-clearly indicates that many patients are maintained on ULT without reassessment of sUA control.
In some cases (Germany, UK, France), lack of disease control resulted in increased utilization of healthcare resources (both gout-attributed and non-gout-attributed) and increased gout-attributed costs. In addition, it should be reiterated that the proportion of patients with gout-attributed GP/PCP visits was consistently and significantly higher in uncontrolled than controlled patients across all four countries.
These findings suggest that in patients with established gout who received ULT treatment, longer persistence and higher adherence to ULT were associated with better control; however, this is only generalizable to the minority of patients with sUA testing. Overall, non-gout-attributed healthcare utilization and costs were higher than gout-attributed healthcare utilization and costs. This finding agrees with other studies assessing the economic burden of gout. Rai et al. [36] identified five studies reporting all-cause direct costs associated with gout patients; depending on the subpopulation studied, the all-cause annual direct costs ranged from $4733 (employed patients) to $18,362 (treatment-refractory patients), while gout-attributed costs ranged from $172 to $6179 across studies.
The assessment of disease control presented here must be viewed in light of the limitations in assessing clinical measures with retrospective data. First, the definition of controlled gout was met if there was no sUA elevation ([6 mg/dl), no diagnosis code for tophus, and no flare documented, while uncontrolled gout was defined by C2 flares or sUA elevation. As described below, in practice, the contribution of the ''tophus'' component of the definition of gout status was minimal, as tophi were under-documented. Incidences of flares can be reduced by prophylactic medications as well as ULT. However, guidelines recommend using prophylaxis for up to 6 months after initiation of ULT, while disease control in our study was assessed following the preindex 12-month period in established gout patients.
The reliability of gout diagnosis within databases in general represents a potential limitation seen for the majority of rheumatic diagnoses [37] . However, such differences are likely an artifact of comparing against disease definitions established to evaluate patients prospectively in a clinical setting or using epidemiologic surveys [38] . It is likely that the rate of uncontrolled disease in the overall population was underestimated, since uncontrolled gout was assessed through a composite endpoint including elevated sUA measurements, occurrence of flares, and tophi, each of which is subject to data-related limitations in estimations. Under-reporting of tophi, in particular, is relevant, as previous work has shown that patients use more resources when tophi are present [39, 40] .
For the USA and France, sUA data were obtained from an external data source for only been more likely to be tested. Also, there is no specific diagnosis code for flares; consequently, identification of flares was based on an algorithm requiring a specific outpatient visit or hospitalization while, in the real world, many flares might be self-treated and therefore remain undetected in primary care databases.
The specificities of the various data sources used for this study should be taken into account when comparing results across the four countries. For instance, PharMetrics Plus is a claims database consisting of commercially insured working adults; this resulted in a US study population younger-and with potentially less severe gout-than in the other countries.
The prevalence of chronic morbidities (especially hypertension and diabetes) was relatively low in the UK versus other published prevalence rates [41] or versus prevalence rates observed for instance in the German or US populations; one possible explanation resides in the specificity of the British National Health Service, where the GP/ PCP plays a role of gatekeeper. Over the course of the patient's affiliation to a practice, the data are centralized at the GP/PCP office; consequently, chronic diseases are coded when they first occur (or at the first visit if the patient is new to the practice) and are less likely to be systematically recoded at each new visit, and may consequently be missed when the look back period is limited to 1 year. A similar bias was observed in the French data, and to some extent probably affects also the German and US data due to the short look back period. The varying level of sUA data availability also resulted in cross-country variation in the assessment of disease control status.
Several data-related factors may also explain the high between-countries variability in estimates of resource utilization and related costs. In particular, the average number of GP/ PCP consultations reported in the UK was much higher than in the USA, Germany, and France, because the CPRD data document all contacts between the patient and the practice (i.e., including phone calls or prescription renewals handled by a nurse); however, the valorization of consultations was made taking this into account and applying distinct unit costs to the different types of consultation.
The cost estimates, both gout-and non-gout-attributed, were in a higher range in the USA, which is because the billing information related to all healthcare services was a primary purpose of and directly available from the claims database, while costs had to be obtained from external sources in the other countries. Compared with the USA, the European databases also lacked some health-related data, likely contributing to underestimation of costs. In France and Germany, limited information (if any) was available on visits to specialists. Hospitalization data were only partially available in European countries, i.e., indirectly (from referrals, so only elective hospitalizations could be captured) in Germany and for a subset of patients in the UK and France; this resulted in low hospitalization rates, low counts of gout-attributed hospitalizations, and low associated cost estimates. More generally, the algorithms used to identify gout-attributed resources were very conservatively defined; also, they were very sensitive to attribution issues resulting from possible misclassification. Finally, even when data allowed for coding of diagnoses, the diagnosis of gout appeared to be 
